Online citations, reference lists, and bibliographies.
← Back to Search

Negative Immune Checkpoint Regulation By VISTA: A Mechanism Of Acquired Resistance To Anti-PD-1 Therapy In Metastatic Melanoma Patients

H. Kakavand, L. Jackett, A. Menzies, Tuba N Gide, M. Carlino, R. Saw, J. Thompson, J. Wilmott, G. Long, R. Scolyer
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Understanding the mechanisms of acquired resistance to anti-PD-1 will allow development of better treatment strategies for cancer patients. This study evaluated potential mechanisms of acquired resistance to anti-PD-1 in longitudinally collected metastatic melanoma patient biopsies. Thirty-four metastatic melanoma biopsies were collected from 16 patients who had initially responded to either anti-PD-1 (n=13) alone or combination of anti-PD-1 and ipilimumab (n=3) and then progressed. Biopsies were taken prior to treatment (PRE, n=12) and following progression of disease (PROG, n=22). Immunohistochemistry was performed on all biopsies to detect CD8, FOXP3, PD-1 and VISTA expression on T-cells and PTEN, β-catenin, PD-L1, HLA-A, and HLA-DPB1 expression in the tumor. The majority of patients showed significantly increased density of VISTA+ lymphocytes from PRE to PROG (12/18) (P=0.009) and increased expression of tumor PD-L1 from PRE to PROG (11/18). Intratumoral expression of FOXP3+ lymphocytes significantly increased (P=0.018) from PRE to PROG (10/18). Loss of tumor PTEN and downregulation of tumor HLA-A from PRE to PROG were each identified in 5/18 and 4/18 PROG biopsies, respectively. Downregulation of HLA-DPB1 from PRE to PROG was present in 3/18 PROG biopsies, whereas nuclear β-catenin activation was only identified in 2/18 PROG biopsies. Negative immune checkpoint regulation by VISTA represents an important potential mechanism of acquired resistance in melanoma patients treated with anti-PD-1. Downregulation of HLA-associated antigen presentation also occurs with acquired resistance. Augmentation of the VISTA immune checkpoint pathway may hold promise as a therapeutic strategy in metastatic melanoma patients, particularly those failing anti-PD-1 therapy, and warrants assessment in clinical trials.
This paper references
10.1038/nrc.2016.2
Acquired resistance to immunotherapy and future challenges
N. Restifo (2016)
Graft-versus-Host Disease in Mouse Models for the Programmed Death-1 Homolog Prevents Cutting Edge: A Monoclonal Antibody Specific
D. Flies (2011)
10.1158/1078-0432.CCR-14-2023
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
H. Kakavand (2015)
10.1146/ANNUREV.IMMUNOL.23.021704.115526
NK cell recognition.
L. Lanier (2005)
10.1038/328267A0
A new member of the immunoglobulin superfamily—CTLA-4
J. Brunet (1987)
10.1084/jem.20100619
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
10.1158/2159-8290.CD-15-0283
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
W. Peng (2016)
10.1158/1078-0432.CCR-11-2479
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
J. Wilmott (2011)
10.1158/2326-6066.CIR-16-0143
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
D. Johnson (2016)
10.1111/pcmr.12098
Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
G. Long (2013)
Discov 2016;6:202–216
S Spranger (2016)
10.1056/NEJMoa1604958
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M. Zaretsky (2016)
10.1038/nature13954
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
10.1080/2162402X.2014.998538
Consensus nomenclature for CD8+ T cell phenotypes in cancer
L. Apetoh (2015)
10.1186/s40425-015-0089-6
A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
Stefani Spranger (2015)
10.1200/JCO.2016.34.15_SUPPL.9503
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
C. Robert (2016)
VISTA regulates
I Le Mercier (2015)
10.1073/pnas.0915174107
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
10.1111/ejh.12228
Interferon‐induced programmed death‐ligand 1 (PD‐L1/B7‐H1) expression increases on human acute myeloid leukemia blast cells during treatment
H. Krönig (2014)
Acquired resistance
NP Restifo (2011)
10.1016/S0959-8049(15)30063-0
3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate
R. Vilain (2015)
Cell Melanoma Res 2013;26:499–508
JS Wilmott (2013)
10.1038/modpathol.2015.110
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases
H. Kakavand (2015)
10.1016/j.jmoldx.2012.08.003
Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
J. Lade-Keller (2013)
10.1182/blood-2009-02-206532
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
F. Romagné (2009)
10.4049/jimmunol.1100660
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
D. Flies (2011)
MHC class I. Immunity 2016;45:280–291
F Romagne (2016)
10.1002/j.1460-2075.1992.tb05481.x
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y. Ishida (1992)
10.1073/pnas.1420370112
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
10.1158/1078-0432.CCR-15-1714
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
J. Madore (2016)
10.1016/j.immuni.2016.07.005
Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I.
Jeanette E Boudreau (2016)
10.1158/0008-5472.CAN-13-1506
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
10.1158/1078-0432.CCR-14-0879
MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
Trevor E Angell (2014)
10.1038/ncomms10582
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
D. Johnson (2016)
10.1038/nature14404
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger (2015)
Effects of BRAF
GV Long (2015)



This paper is referenced by
10.1007/s11912-020-00983-y
Alternative Checkpoints as Targets for Immunotherapy
Ayush Pant (2020)
10.1038/s41590-019-0512-0
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
L. Andrews (2019)
10.1016/j.intimp.2020.106700
Mechanisms of immune escape in the cancer immune cycle.
S. Tang (2020)
10.1186/s13045-020-00917-y
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Xing Huang (2020)
10.1080/14737159.2017.1398083
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
P. Hofman (2017)
10.1038/s41379-019-0364-z
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma
S. Muller (2019)
10.1007/s11523-018-0595-9
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
Alice Tzeng (2018)
10.3390/cancers12102870
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
I. Falcone (2020)
10.1055/S-0043-121594
Immuntherapie – Die neue Ära in der Onkologie
Benjamin A Kansy (2018)
10.1080/13543784.2019.1559297
CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy
B. Szóstak (2019)
10.1007/s00262-018-2227-8
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
S. Xie (2018)
10.1016/j.ccell.2020.03.017
Acquired Resistance to Immune Checkpoint Inhibitors.
A. Schoenfeld (2020)
10.1186/s12885-018-4435-1
VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma
M. Zhang (2018)
10.1007/s00262-018-2169-1
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
Lawrence F. Kuklinski (2018)
10.1158/1078-0432.CCR-18-4011
Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
J. Edwards (2019)
10.1016/j.clgc.2019.03.009
PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Miles Hsu (2019)
10.1038/s42255-020-00280-9
Metabolic and epigenetic regulation of T-cell exhaustion.
Fabien Franco (2020)
10.1016/j.cytogfr.2020.02.002
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
Geng Wang (2020)
Translating immune characteristics of metastatic tumors into therapeutic targets for cervical cancer
A. M. Heeren (2018)
10.1007/s00262-019-02434-5
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
Liju Zong (2019)
10.1097/PPO.0000000000000303
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
T. S. Nowicki (2018)
10.1080/13543784.2020.1793956
New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials
Danilo Rocco (2020)
10.1136/esmoopen-2020-000683
New emerging targets in cancer immunotherapy: the role of VISTA
M. Tagliamento (2020)
10.1055/s-0043-121594
Immunotherapy – The New Era of Oncology
B. Kansy (2018)
10.1038/s41388-020-1373-6
Melanoma stem cell maintenance and chemo-resistance are mediated by CD133 signal to PI3K-dependent pathways
Siraj M. El Jamal (2020)
10.1038/s41467-020-15726-7
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
J. H. Lee (2020)
10.1080/2162402X.2018.1431088
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
E. Ahern (2018)
10.1097/CM9.0000000000001082
Emerging immunotherapy targets in lung cancer
Hao-Hua Zhu (2020)
10.3390/genes11060703
Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
R. Saleh (2020)
10.1016/BS.ACR.2019.05.001
Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches.
Aras Toker (2019)
10.1038/s41586-019-1674-5
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston (2019)
10.1101/597716
Structure and Functional Binding Epitope of V-domain Ig Suppressor of T-cell Activation (VISTA)
Nishant Mehta (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar